Cargando…

Pharmacologic therapeutic options for thromboprophylaxis in COVID-19

Detalles Bibliográficos
Autores principales:	Kow, Chia Siang, Hasan, Syed Shahzad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321015/ https://www.ncbi.nlm.nih.gov/pubmed/32596786 http://dx.doi.org/10.1007/s11239-020-02200-w

Ejemplares similares

The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Pharmacological Management of Obese Patients with Type 2 Diabetes amid COVID-19 Pandemic
por: Kow, Chia Siang, et al.
Publicado: (2020)

Azithromycin in patients with COVID-19: Friend or foe?
por: Kow, Chia Siang, et al.
Publicado: (2021)

Revascularization in COVID-19 patients with renal infarction
por: Kow, Chia Siang, et al.
Publicado: (2021)

Use of Azithromycin in COVID-19: A Cautionary Tale
por: Kow, Chia Siang, et al.
Publicado: (2020)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Macrolides for patients with COVID-19 and concurrent pertussis infection
por: Kow, Chia Siang, et al.
Publicado: (2021)

The use of antimotility drugs in COVID-19 associated diarrhea
por: Kow, Chia Siang, et al.
Publicado: (2021)

Cerebral Venous Thrombosis following COVID-19 Vaccination
por: Kow, Chia Siang, et al.
Publicado: (2021)

Neurohormonal treatment in tako-tsubo cardiomyopathy precipitated by COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Potential interactions between COVID-19 vaccines and antiepileptic drugs
por: Kow, Chia Siang, et al.
Publicado: (2021)

Special consideration in the dosing of medications for patients with COVID-19 and acute kidney injury
por: Kow, Chia Siang, et al.
Publicado: (2020)

Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis
por: Kow, Chia Siang, et al.
Publicado: (2021)

Revascularization strategy in patients with acute ST-elevation myocardial infarction amid COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2021)

A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Colchicine for COVID-19: Hype or hope?
por: Kow, Chia Siang, et al.
Publicado: (2022)

Insulin therapy in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Probiotics for the Prevention of COVID-19 Sequelae
por: KOW, CHIA SIANG, et al.
Publicado: (2022)

Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Metformin therapy in COVID-19: inhibition of NETosis
por: Kow, Chia Siang, et al.
Publicado: (2022)

Statin Therapy in COVID-19: Inhibition of NETosis
por: Kow, Chia Siang, et al.
Publicado: (2022)

The use of dornase alfa in patients with COVID-19
por: Ramachandram, Dinesh Sangarran, et al.
Publicado: (2023)

Use of sulforaphane in COVID-19: Clinical trials are needed
por: Kow, Chia Siang, et al.
Publicado: (2022)

Anticoagulant approach in COVID-19 patients with cerebral venous thrombosis
por: Kow, Chia Siang, et al.
Publicado: (2020)

Statin use in patients with diabetes amid COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2022)

Should COVID-19 be considered cardiovascular disease risk equivalent?
por: Kow, Chia Siang, et al.
Publicado: (2023)

Metformin in COVID-19: clinical trials are needed to prove its benefits
por: Kow, Chia Siang, et al.
Publicado: (2022)

Use of aspirin for primary prevention in patients with diabetes during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2021)

Combination Therapy with CCBs and RAS Inhibitors to Counteract Endothelial Dysfunction in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2022)

Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2022)

Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2022)

Melatonin: Revisited Role as Vaccine Adjuvant During Outbreaks of COVID-19 Caused by the Delta Variant
por: Kow, Chia Siang, et al.
Publicado: (2021)

Famotidine: A potential mitigator of mast cell activation in post-COVID-19 cognitive impairment
por: Kow, Chia Siang, et al.
Publicado: (2023)

Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’
por: Kow, Chia Siang, et al.
Publicado: (2023)

Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis
por: Kow, Chia Siang, et al.
Publicado: (2021)

Concurrent Antibiotic Therapy in Disseminated Strongyloidiasis
por: Kow, Chia Siang, et al.
Publicado: (2020)

Acute Heart Failure in Coronavirus Disease 2019 and the Management of Comedications
por: Kow, Chia Siang, et al.
Publicado: (2020)

Tratamiento neurohormonal en miocardiopatía de tako-tsubo precipitada por COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Prevalence of Frailty in Patients with COVID-19: A Meta-Analysis
por: Kow, Chia Siang, et al.
Publicado: (2020)

El uso de agentes antiplaquetarios para la tromboprofilaxis arterial en la COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bntlfj48qjjklv5i8sn11t26b1